Abstract
Inhaled epinephrine is the only current over-the-counter (OTC) option for the management of mild asthma in the United States (US). Given concerns of beta2-agonist overuse, and evidence-based guidelines recommending as-needed inhaled corticosteroid-formoterol as first-line reliever therapy, we examined the cost-effectiveness of OTC as-needed budesonide-formoterol compared to as-needed inhaled epinephrine and a no OTC inhaler option.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
